NOVARTIS AG NOVARTIS IN ADVANCED TALKS TO BUY CYTOKINETICS - WSJ
Novartis In Advanced Talks To Buy Cytokinetics - Wsj…
January 08, 2024 at 11:27 pm IST
Share
Share
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 95.89 CHF | -0.12% |
|
+2.94% | +12.98% |
| 24/06 | Foreign banks target Switzerland after UBS takeover of Credit Suisse | RE |
| 24/06 | NOVARTIS AG : Barclays reaffirms its Sell rating | ZD |
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows:
- oncology (29.9%);
- immunology (17.2%);
- cardiovascular, renal and metabolic diseases (14.1%);
- neuroscience (8.9%).
The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products.
At the end of 2023, Novartis AG had 33 production sites worldwide.
Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Sector
Pharmaceuticals
Calendar
18/07/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
107.2
USD
Average target price
110.3
USD
Spread / Average Target
+2.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.98% | 219B | |
| +55.19% | 815B | |
| +47.26% | 654B | |
| -6.09% | 354B | |
| +21.92% | 337B | |
| +18.40% | 247B | |
| +3.64% | 229B | |
| +10.86% | 171B | |
| -2.78% | 159B | |
| +1.24% | 122B |
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- Novartis In Advanced Talks To Buy Cytokinetics - Wsj…
